MOBility Disorders Assessment in Patients With Mild COGnitive Disorders
Mild cognitive impairment (MCI) is defined by lower performance in one or more cognitive domains with preservation of independence in functional abilities. Sixteen percent of community-dwelling older people (over 65 years) live with MCI. They are both cognitively and physically vulnerable. From a cognitive perspective,
| Condition(s) | Cognitive Dysfunction |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Mild cognitive impairment (MCI) is defined by lower performance in one or more cognitive domains with preservation of independence in functional abilities. Sixteen percent of community-dwelling older people (over 65 years) live with MCI. They are both cognitively and physically vulnerable. From a cognitive perspective, they are susceptible to converting to the dementia stage at an annual rate of 10%. From a physical perspective, the proportion of slow gait or neurological gait abnormalities can reach 46% in the population with MCI. Falls in turn increase the risk of accelerated cognitive decline and the risk of institutionalization. In the absence of a curative treatment for dementia, it is essential to have an effective and personalized prevention strategy by identifying the predictive fa |
| Who can participate | Inclusion Criteria: * Patient being diagnosed with MCI, according to the 2011 criteria * Able to walk 4 meters with or without technical assistance * Comprehension of French language allowing the realization of the neuropsychological assessment Exclusion Criteria: * Severe visual or hearing impairment that does not allow the assessment * Severe pathology that makes follow-up impossible * Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security insurance, refusal to sign consent form * Under legal protection (guardianship, curatorship, safeguard of justice) |
| Ages | 65 Years |
| Sex | All |
| Lead sponsor | University Hospital, Lille |
| Locations | Lille, France; Lille, France |
| Start date | 2022-09-09 |
| NCT ID | NCT05273125 |
| Official listing | https://clinicaltrials.gov/study/NCT05273125 |